Plasmodium falciparum ATPase type IV (PfATP4)

PfATP4 (Plasmodium falciparum ATPase 4) is a P-type cation-transporter ATPase that functions as a sodium (Na+) efflux pump, playing an essential role in maintaining Na+ homeostasis within the malaria parasite Plasmodium falciparum. This protein is a validated and highly druggable target for new antimalarial therapies due to its unique presence in lower eukaryotes and absence from humans. PfATP4 actively transports Na+ out of the parasite cytoplasm against its concentration gradient, keeping intracellular Na+ levels low despite the high-Na+ environment of infected red blood cells. Disruption of PfATP4 function leads to rapid accumulation of intracellular Na+, increased pH, cell swelling, and ultimately lysis or death of both isolated parasites and infected erythrocytes. Several structurally diverse chemical classes have been identified as potent inhibitors, including spiroindolones, dihydroisoquinolones, aminopyrazoles and pyrazoleamides. Resistance arises through point mutations within PfATP4 that reduce inhibitor binding or alter pump function, but these mutations may also impair overall protein efficiency or localization—sometimes resulting in reduced fitness for resistant parasites. Compounds targeting PfATP4 demonstrate rapid parasiticidal activity, efficacy against drug-resistant malaria strains, and potential as next-generation antimalarials due to their novel mode-of-action distinct from current therapies.

Inhibition of sodium efflux, leading to toxic accumulation of intracellular sodium, disruption of osmotic balance and pH regulation, and parasite death.